Other languages Alector, Inc.

Equities

ALEC

US0144421072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
4.81 ^USD	-8.38%		-5.50%	-39.72%

Apr. 17	Certain Restricted Stock Units of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
Apr. 17	Certain Options of Alector, Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alector, Inc. Announces Board Changes	Mar. 21
Alector, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Alector, Inc. Provides Revenue Guidance for the Year Ending 2024	Feb. 27
Alector, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer?S Disease	Feb. 08
Alector, GSK Say FDA Grants Breakthrough Therapy Label For Frontotemporal Dementia Treatment	Feb. 07
GSK : statut de traitement novateur dans la démence	Feb. 07
Alector, Inc. Announces the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation to Latozinemab	Feb. 07
Alector Closes $75 Million Public Stock Offering	Jan. 19
Alector Tumbles After Pricing $75 Million Stock Offering	Jan. 17
Sector Update: Health Care Stocks Decline Pre-Bell Wednesday	Jan. 17
Alector Plans Common Stock Offering; Shares Fall After-Hours	Jan. 16
Alector Shares Rise After Stifel Upgrade	Dec. 14
Alector Insider Sold Shares Worth $132,500, According to a Recent SEC Filing	Dec. 07
Alector, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023	Nov. 07
Sector Update: Health Care Stocks Gain Premarket Monday	23-10-30
Alector Reaches Enrollment Target for Latozinemab Phase 3 Trial	23-10-27
Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)	23-10-27
Alector Insider Sold Shares Worth $3,000,000, According to a Recent SEC Filing	23-09-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alector, Inc.

Equities

ALEC

US0144421072

Other languages

Filters